Proving Nanoscale Chiral Interactions of Cyclodextrins and Propranolol Enantiomers by Means of SERS Measurements Performed on a Solid Plasmonic Substrate.
Raman
SERS
chiral interactions
cyclodextrins
quantum calculations
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
01 Oct 2021
01 Oct 2021
Historique:
received:
27
08
2021
revised:
17
09
2021
accepted:
27
09
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
Chiral separation is an important issue for the pharmaceutical industry. Over the years, several separation methods have been developed, mainly based on chromatography. Their working principle is based on the formation of transient diastereoisomers, but the very subtle nanoscale interactions responsible for separation are not always understood. Recently, Raman and surface-enhanced Raman (SERS) spectroscopy have provided promising results in this field. Here we present Raman/SERS experimental data that provide useful information concerning the nanoscale interactions between propranolol enantiomers and α, β, and γ cyclodextrins. Raman spectroscopy was used to prove the formation of host-guest intermolecular complexes having different geometries of interaction. The occurrence of new vibrational bands and a change in the intensities of others are direct proofs of complexes' formation. These observations were confirmed by DFT calculations. By performing SERS measurements on a new type of plasmonic substrate, we were able to prove the intermolecular interactions responsible for PRNL discrimination. It turned out that the interaction strength between the substrate and the intermolecular complexes is of paramount importance for SERS-based chiral discrimination. This approach could represent a very good starting point for the evaluation of molecular interactions manifesting between other pharmaceutical compounds and different classes of chiral selectors.
Identifiants
pubmed: 34683887
pii: pharmaceutics13101594
doi: 10.3390/pharmaceutics13101594
pmc: PMC8539071
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii
ID : PN-III-P4-ID-PCCF-2016-0112
Références
J Am Chem Soc. 2010 Aug 18;132(32):10970-2
pubmed: 20698645
Chem Rev. 2015 Nov 25;115(22):12320-406
pubmed: 26566008
Chemphyschem. 2011 Jun 6;12(8):1529-35
pubmed: 21161974
Phys Rev B Condens Matter. 1988 Jan 15;37(2):785-789
pubmed: 9944570
J Chromatogr A. 2000 Apr 14;875(1-2):3-25
pubmed: 10839137
Nanomaterials (Basel). 2020 Jun 21;10(6):
pubmed: 32575924
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Int J Pharm. 2019 Oct 5;569:118593
pubmed: 31398371
Talanta. 2012 Nov 15;101:53-8
pubmed: 23158290
Science. 2018 Jun 22;360(6395):1331-1334
pubmed: 29748324
Phys Chem Chem Phys. 2015 Jan 14;17(2):1281-9
pubmed: 25420457
J Phys Chem A. 2011 Aug 4;115(30):8511-9
pubmed: 21728366
J Phys Chem B. 2006 Feb 2;110(4):1944-8
pubmed: 16471765
J Sep Sci. 2010 Jun;33(11):1617-24
pubmed: 20437416
Acc Chem Res. 2008 Dec;41(12):1653-61
pubmed: 18630932
J Pharm Biomed Anal. 2002 Jan 15;27(3-4):373-99
pubmed: 11755740
J Chromatogr A. 2016 Oct 7;1467:56-78
pubmed: 27318504